Are MedReleaf Corp. Owners Looking to Cash Out?

MedReleaf Corp. (TSX:LEAF), the fourth largest pot stock by market capitalization, is actively looking for buyers.

| More on:
The Motley Fool

For the better part of the past year, the cannabis industry has kept the TSX afloat. As the market has struggled to achieve positive returns, the Canadian Marijuana Index has returned a whopping 129%. Year-to-date (YTD), the market has not been as kind to the industry, however. It is down approximately 11% despite — or perhaps because of — several high-profile takeovers. Yesterday, the news came out that one of the largest players in the industry, MedReleaf Corp. (TSX:LEAF) was actively seeking a buyer.

Quick exit

It was less than a year ago that MedReleaf completed the cannabis industry’s largest IPO in North America. On June 1, 2017, it raised $75 million on the open market, which valued the company at $869 million. It priced its shares at $9.50. As of today, its share price has almost tripled and it has a $2.195 market capitalization. Are the owners looking for a quick exit based on the recent strength of the industry? It’s quite possible.

Rumoured buyer

It appears that MedReleaf has reached out to several of the larger players in the industry. Canopy Growth Corp. (TSX:WEED), Aurora Cannabis Inc. (TSX:ACB) and Aphria Inc. (TSXV:APH) have all been approached. Surprisingly, Aurora Cannabis appears to be the front-runner and is in serious negotiations with MedReleaf.

Aurora is fresh off the largest acquisition in the history of the cannabis sector. The ink is barely dry on its $1.1 billion dollar deal for CanniMed Therapeutics in an all-stock deal. The company only announced the completed acquisition this past Tuesday, May 1. Aurora’s purchase of CanniMed began as a hostile takeover at $24 per share. In the end, Aurora upped its offer by almost 80% to $43 per share to gain CanniMed support. CanniMed’s shareholders made out like bandits, while Aurora’s shareholders have struggled. The latter company’s share price has lost 42% of its value since the new offer was announced.

If Aurora were to acquire MedReleaf, it would create the largest pot company by market capitalization. The question that Aurora shareholders must weigh is this: is it too much, too soon?

All-stock deals are bad for the acquirers

Research suggests that shareholders of companies being acquired benefit most from takeovers. Likewise, in all-stock deals such as the aforementioned CanniMed acquisition, evidence suggests that shareholders of the acquiring company often lose out. The reason is simple: in an all-stock deal, the current shareholders of the acquiring company lose through the dilution of their equity stake in the new company.

MedReleaf’s share price is currently down 20% YTD and approximately 31% from its 52-week high of $31.25. Given the high premiums paid for CanniMed and more recently Aphria’s acquisition of Nuuvera, it isn’t unrealistic to expect that MedReleaf shareholders would expect nothing less than a 40% premium as of its most recent closing price.

There is no doubt that the cannabis industry is going to consolidate. As a shareholder, I would much rather be the acquired party than the acquirer in these deals. MedReleaf is thus worth watching.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Mat Litalien has no position in any of the stocks mentioned.  

More on Investing

Path to retirement
Dividend Stocks

Retire Rich: TFSA Stocks to Power Your Golden Years

Investing in your TFSA early has huge benefits. Here’s a look at some stocks for your TFSA that can power…

Read more »

stock research, analyze data
Tech Stocks

2 Artificial Intelligence-Powered Growth Stocks to Buy Right Now

These growth stocks are excellent buys today, and much of the reason for that is powered by their use of…

Read more »

Retirees sip their morning coffee outside.

TFSA: 3 Top TSX Stocks for Your $6,500 Contribution

These three TSX stocks could be ideal additions to your TFSA in this uncertain outlook.

Read more »

edit Sale sign, value, discount

Dollarama: A Bargain Stock for a Bargain Hunter

Dollarama continues to fire on all cylinders, and with it now trading off its 52-week high, it's one of the…

Read more »

Bank Stocks

Is This the Perfect Time to Invest in Canadian Banking Stocks?

Canadian banking stocks have continued to perform pretty poorly over the last few months, but that could mean a great…

Read more »

woman retiree on computer

Retirees: Here’s How to Boost Your CPP Pension

Retirement planning is best done when considering not only your CPP pension, but also your investments in income-producing stocks like…

Read more »

An airplane on a runway
Stocks for Beginners

Is Bombardier Stock Worth Buying on the Dip in June 2023?

These key factors make Bombardier stock look undervalued in June 2023 to buy for the long term.

Read more »

money cash dividends
Dividend Stocks

These TSX Telecom Stocks Are Dialling Up Impressive Profits 

Two telecom stocks are dialing up dividend profits for shareholders while inflation and interest are slowing dividends for some companies.

Read more »